The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Adverum Biotechnologies, Inc. | Common Stock | 00773U108 | 3,815,366 | 5,068,233 | SH | OTR | 0 | 5,068,233 | 0 | ||
Aligos Therapeutics, Inc. | Common Stock | 01626L105 | 1,540,733 | 2,320,381 | SH | OTR | 0 | 2,320,381 | 0 | ||
CRISPR Therapeutics AG | Common Shares | H17182108 | 31,209,731 | 498,558 | SH | OTR | 0 | 498,558 | 0 | ||
Gritstone Bio, Inc. | Common Stock | 39868T105 | 7,264,746 | 3,561,150 | SH | OTR | 0 | 3,561,150 | 0 | ||
Passage Bio, Inc. | Common Stock | 702712100 | 5,009,367 | 4,959,769 | SH | OTR | 0 | 4,959,769 | 0 | ||
RayzeBio, Inc. | Common Stock | 75525N107 | 320,682,869 | 5,158,161 | SH | OTR | 0 | 5,158,161 | 0 | ||
Repare Therapeutics, Inc. | Common Stock | 760273102 | 19,320,596 | 2,646,657 | SH | OTR | 0 | 2,646,657 | 0 |